{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_3pcdykhnkmm5sb3lhu7a","seq":1266854,"kind":"article","title":"Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trial","url":"https://www.medicaldaily.com/survodutide-phase-3-type-2-diabetes-weight-loss-nejm-479379","summary":"Survodutide cut weight by up to 13.1% in adults with type 2 diabetes in a company-funded trial. It is not approved, and 18% quit due to side effects.","published":"2026-10-02T02:38:54Z","seen":"2026-10-02T04:54:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1248127","name":"Boehringer","type":"org"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.8,"sentiment":"positive","tone":0.27,"political":0.02},{"id":"n_fwcvrxgfbacgkqb4rnkq","seq":963864,"kind":"article","title":"Kein Börsengang: Boehringer bleibt unabhängig","title_en":"No IPO: Boehringer remains independent","url":"https://www.apotheke-adhoc.de/nachrichten/detail/markt/kein-boersengang-boehringer-bleibt-unabhaengig","summary":"Für den in Familienbesitz befindlichen Pharma-Riesen Boehringer Ingelheim ist ein Börsengang kein Thema. „Unsere finanzielle Unabhängigkeit hat für uns oberste Priorität“, sagte Konzernschef Shashank Deshpande dem „Manager Magazin“. Der Deutschen Presse-Agentur in Mainz sagte er anschließend auf Anfrage: „Boehringer Ingelheim strebt keine Börsenlistung an.“ Man wolle aus eigener Stärke weiter wachsen, sei und bleibe eigenständig. „Ein Verkauf oder IPO ist nicht…","published":"2026-09-30T17:22:48Z","seen":"2026-09-30T17:22:48Z","lang":"de","country":"DE","source":{"id":"kite-apotheke-adhoc-de-8cd12d","name":"apotheke-adhoc.de","domain":"apotheke-adhoc.de"},"via":"kite-apotheke-adhoc-de-8cd12d","topics":["healthcare","germany"],"entities":[{"id":"Q1248127","name":"Boehringer","type":"org"}],"image":"https://www.apotheke-adhoc.de/fileadmin/user_upload/redaktion/2025/KW16/boehringer_Deshpande_Shashank_63444_boehringer.jpg","story":"st_ad3pysk73ue7kyaz6neq","category":"economy-business","category_p":0.87,"sentiment":"neutral","tone":0.0,"political":0.18},{"id":"n_ad3pysk73ue7kyaz6neq","seq":923858,"kind":"article","title":"Pharma: Boehringer bleibt unabhängig – kein Börsengang geplant","title_en":"Pharma: Boehringer remains independent - no stock market listing planned","url":"https://www.zeit.de/news/2026-09/30/boehringer-bleibt-unabhaengig-kein-boersengang-geplant","summary":"None","published":"2026-09-30T13:58:47Z","seen":"2026-09-30T14:15:34Z","lang":"de","country":"DE","source":{"id":"kite-newsfeed-zeit-de-8957d1","name":"newsfeed.zeit.de","domain":"newsfeed.zeit.de"},"via":"kite-newsfeed-zeit-de-8957d1","topics":["hamburg","news"],"authors":["DIE ZEIT: News -"],"entities":[{"id":"Q1248127","name":"Boehringer","type":"org"}],"image":"https://img.zeit.de/news/2026-09/30/boehringer-bleibt-unabhaengig-kein-boersengang-geplant-image-group/original__640x360","story":"st_ad3pysk73ue7kyaz6neq","category":"economy-business","category_p":0.8,"sentiment":"neutral","tone":-0.04,"political":0.12}]}